Skip to main content
Premium Trial:

Request an Annual Quote

Protagen, Bayer Partner on Biomarkers for Endometriosis

NEW YORK (GenomeWeb News) – Protagen today announced a collaboration with Bayer HealthCare Pharmaceuticals aimed at clinically validating diagnostic biomarkers for endometriosis.

The project is the third between the companies and builds on an endometriosis biomarker study performed last year. Protagen and Bayer initially partnered in 2008 to evaluate Protagen's UNIarray technology for patient stratification and predictive diagnosis of atrial fibrillation.

The current project will use the technology for the predictive diagnosis of endometriosis. Currently, the illness is diagnosed by laparoscopy.

Aside from endometriosis, the UNIarray technology is being applied to autoimmune diseases, chronic inflammatory diseases, and cancer. The firm's other partners include Biogen-Idec and SuppreMol, Peter Schulz-Knappe, chief scientific officer and executive vice president of diagnostics for Protagen, said in a statement.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.